1. Home
  2. LQDA vs PBI Comparison

LQDA vs PBI Comparison

Compare LQDA & PBI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • LQDA
  • PBI
  • Stock Information
  • Founded
  • LQDA 2004
  • PBI 1920
  • Country
  • LQDA United States
  • PBI United States
  • Employees
  • LQDA N/A
  • PBI N/A
  • Industry
  • LQDA Biotechnology: Pharmaceutical Preparations
  • PBI Office Equipment/Supplies/Services
  • Sector
  • LQDA Health Care
  • PBI Miscellaneous
  • Exchange
  • LQDA Nasdaq
  • PBI Nasdaq
  • Market Cap
  • LQDA 1.9B
  • PBI 2.0B
  • IPO Year
  • LQDA 2018
  • PBI N/A
  • Fundamental
  • Price
  • LQDA $24.53
  • PBI $10.03
  • Analyst Decision
  • LQDA Strong Buy
  • PBI
  • Analyst Count
  • LQDA 9
  • PBI 0
  • Target Price
  • LQDA $32.67
  • PBI N/A
  • AVG Volume (30 Days)
  • LQDA 2.2M
  • PBI 2.4M
  • Earning Date
  • LQDA 11-03-2025
  • PBI 10-29-2025
  • Dividend Yield
  • LQDA N/A
  • PBI 3.19%
  • EPS Growth
  • LQDA N/A
  • PBI N/A
  • EPS
  • LQDA N/A
  • PBI 0.45
  • Revenue
  • LQDA $19,322,000.00
  • PBI $1,931,125,000.00
  • Revenue This Year
  • LQDA $424.31
  • PBI N/A
  • Revenue Next Year
  • LQDA $359.32
  • PBI N/A
  • P/E Ratio
  • LQDA N/A
  • PBI $22.42
  • Revenue Growth
  • LQDA 30.20
  • PBI N/A
  • 52 Week Low
  • LQDA $9.71
  • PBI $6.88
  • 52 Week High
  • LQDA $29.94
  • PBI $13.11
  • Technical
  • Relative Strength Index (RSI)
  • LQDA 52.65
  • PBI 29.58
  • Support Level
  • LQDA $22.05
  • PBI $9.89
  • Resistance Level
  • LQDA $24.34
  • PBI $11.98
  • Average True Range (ATR)
  • LQDA 1.26
  • PBI 0.40
  • MACD
  • LQDA 0.10
  • PBI -0.13
  • Stochastic Oscillator
  • LQDA 60.51
  • PBI 5.98

About LQDA Liquidia Corporation

Liquidia Corp is a United States-based biopharmaceutical company focused on the development, manufacturing, and commercialization of products that address unmet patient needs, with the current focus directed towards the treatment of pulmonary hypertension (PH) and pulmonary hypertension associated with interstitial lung disease. It conducts research, development, and manufacturing of novel products by applying its proprietary PRINT technology, a particle engineering platform, to enable the precise production of uniform drug particles. Its product includes YUTREPIA (treprostinil) inhalation powder, for the treatment of pulmonary arterial hypertension. The company also generates revenue from the sale of Treprostinil Injection through an agreement between its subsidiary and the manufacturer.

About PBI Pitney Bowes Inc.

Pitney Bowes Inc is a technology-driven company that provides SaaS shipping solutions, mailing innovation, and financial services to clients around the globe. The company's reportable segments are SendTech Solutions and Presort Services. SendTech Solutions includes the revenue and related expenses from physical and digital mailing and shipping technology solutions, financing, services, supplies and other applications to help simplify and save on the sending, tracking and receiving of letters, parcels and flats. Presort Services includes the revenue and related expenses from sortation services to qualify large volumes of First Class Mail, Marketing Mail and Marketing Mail Flats/Bound Printed Matter for postal worksharing discounts. It derives maximum revenue from SendTech Solutions.

Share on Social Networks: